Related Experiment Video
Updated: Jun 21, 2026
09:36
Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
Aerosolized antibiotics in critically ill ventilated patients
1Pulmonary Critical Care Division, State University of New York, Department of Medicine, Stony Brook, New York 11794-8172, USA. lbpalmer@notes.cc.sunysb.edu
Current Opinion in Critical Care
|August 7, 2009
Summary
Aerosolized antimicrobial therapy offers a promising approach to treating respiratory infections in mechanically ventilated patients. This method delivers high drug concentrations directly to the lungs, reducing systemic toxicity and combating resistant pathogens.
Area of Science:
- Critical Care Medicine
- Pulmonology
- Infectious Diseases
Background:
- The rise of antibiotic resistance necessitates novel treatment strategies for respiratory tract infections.
- Intravenous antibiotics in mechanically ventilated patients can lead to systemic toxicity.
- Aerosolized antibiotics, historically used for prophylaxis, are being re-evaluated for therapeutic use.
Purpose of the Study:
- To review recent clinical data on the efficacy of aerosolized antimicrobial therapy.
- To assess the role of aerosolized antibiotics in treating respiratory infections in ICU patients.
Main Methods:
- Review of recent clinical studies and data.
- Analysis of therapeutic protocols for aerosolized antibiotic delivery.
Main Results:
- Aerosolized antibiotics achieve high lung drug concentrations, minimizing systemic side effects.
- There is a resurgence in interest for using aerosolized antibiotics for ventilator-associated tracheobronchitis (VAT) and pneumonia (VAP).
- Emerging data suggest efficacy against highly resistant organisms when used in targeted protocols.
Conclusions:
- Aerosolized antibiotic therapy is potentially effective for respiratory tract infections in mechanically ventilated patients.
- This approach is particularly beneficial for proximal airway infections, VAT, and VAP, especially with resistant organisms.
- Targeted, time-limited protocols enhance the efficacy of aerosolized antibiotic treatment.
Related Concept Videos
01:29Acute Respiratory Failure-V
The treatment for acute respiratory failure varies based on factors like the underlying cause, overall health, and severity. A collaborative healthcare team is essential for early detection, often through arterial blood gas analysis. Identifying the cause is the primary goal, with treatment strategies adjusted for ventilation/perfusion (V/Q) mismatch, shunting, or diffusion impairment.
Ensure that patients are monitored continuously for their response to therapy, including changes in...
Ensure that patients are monitored continuously for their response to therapy, including changes in...
01:25Transmission-based Precautions II: Airborne and Protective Environment
Transmission-based precautions are for patients infected or suspected to be infected (or colonized) with organisms posing a significant risk to others. The transmission precautions include airborne and protective environment precautions.
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
01:23Inhaled Medications
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
01:28Pneumonia IV: Management
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:25Inhalation Anthrax
Anthrax is a zoonotic disease caused by Bacillus anthracis, a Gram-positive, spore-forming bacterium. It primarily affects herbivorous animals but can be transmitted to humans through skin contact, ingestion, or inhalation of spores.Cutaneous anthrax, the most common form, typically results from direct contact with bacterial spores through skin abrasions and is generally less severe. Gastrointestinal anthrax results from eating undercooked or contaminated meat. It affects the mouth, throat, or...
01:25Mechanism of Antibiotic Resistance in MRSA
Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...